Phase I trial with recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma.

Alterations of immunological parameters were analysed in patients with advanced malignancies during a phase I trial with rIL-2. Five-day infusions of rIL-2 at doses from 1 x 10(6) to 24 x 10(6) biological response modifiers program (BRMP) U/m2 per day were given to 29 patients, with a minimum of thr...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Farace, F, Mathiot, C, Brandely, M, Tursz, T, Dorval, T, Pouillart, P, Triebel, F, Hercend, T, Fridman, W H
Formato: Artigo
Idioma:Inglês
Publicado: 1990
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC1535125/
https://ncbi.nlm.nih.gov/pubmed/2122928
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares